Results 91 to 100 of about 6,607 (210)

Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis [PDF]

, 1994
Transferrin, an iron-transporting serum glycoprotein, is efficiently taken up into cells by the process of receptor-mediated endocytosis. Transferrin receptors are found on the surface of most proliferating cells, in elevated numbers on erythroblasts and
Matt Cotten, David Curiel, Curiel, David T., Wagner, Ernst, Ernst Wagner, Cotten, Matt   +5 more
core   +1 more source

Everolimus enhances immunotoxin action through coordinated down-regulation of protein synthesis and is also effective in a tumor xenograft model.

, 2016
A. Confirmation results demonstrating that everolimus enhances the cellular toxicity of the HA22, SS1P and HB21PE40 immunotoxins in multiple cell types.
Lesley Mathews Griner (2851961), Antonella Antignani (3074406), Evan Angelus (3074412), Manjie Huang (3074409), David J. FitzGerald (3074403), Nathan Simon (3074400), Matteo Pasetto (3074415), Craig J. Thomas (17880), Rajarshi Guha (182356), Ira Pastan (303807), Jonathan Keller (2400), Marc Ferrer (191300)   +11 more
core   +1 more source

Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts

, 2011
Purpose: The success of immunotoxin therapy of cancer is limited by host production of neutralizing antibodies, which are directed toward the Pseudomonas exotoxin A (PE) component.
Ira Pastan, Daniel H. Fowler, Justin Taylor, Shirin Treadwell, Raffit Hassan, Masanori Onda, Paul R. Massey, Miriam E. Mossoba, Elad Sharon   +8 more
core   +1 more source

Targeted Apoptosis Activation with GrB/scFvMEL Modulates Melanoma Growth, Metastatic Spread, Chemosensitivity, and Radiosensitivity

Neoplasia: An International Journal for Oncology Research, 2006
GrB/scFvMEL, a fusion protein composed of human granzyme B (GrB) and the single-chain antibody scFvMEL, targets melanoma gp240 antigen and exerts impressive cytotoxic effects by inducing apoptosis. We evaluated the effects of GrB/scFvMEL on chemotherapy,
Yuying Liu, Weihe Zhang, Ting Niu, Lawrence H. Cheung, Anupama Munshi, Raymond E. Meyn, Jr., Michael G. Rosenblum   +6 more
doaj   +1 more source

Countering immunotoxin immunogenicity [PDF]

British Journal of Cancer, 2016
The entry of antibody-based drugs into mainstream medicine has provided the oncologist with new therapeutic tools that have begun to transform the treatment of cancer (Scott et al, 2012; Lee et al, 2013). Toxicity profiles and cell killing mechanism(s) exhibited by antibody and small-molecule cytotoxic therapies are largely non-overlapping, thus ...
openaire   +2 more sources

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy

Frontiers in Oncology, 2018
Acute Lymphoblastic Leukemia (ALL) remains the most frequent cause of cancer-related mortality in children and novel therapies are needed for the treatment of relapsed/refractory childhood ALL.
Monika Bokori-Brown, Jeremy Metz, Peter G. Petrov, Francis Mussai, Carmela De Santo, Neil J. Smart, Sarah Saunders, Bridget Knight, Ira Pastan, Richard W. Titball, C. Peter Winlove   +10 more
doaj   +1 more source

Improvement of a Recombinant Anti-Monkey Anti-CD3 Diphtheria Toxin Based Immunotoxin by Yeast Display Affinity Maturation of the scFv

, 2016
Recently, a bivalent recombinant anti-human CD3 diphtheria toxin (DT) based immunotoxin derived from the scFv of UCHT1 antibody has been made that shows enhanced bioactivity and is free from the side effects of Fc receptor interaction.
Zhirui Wang (629192), Yuan Yi Liu (2491810), Scott Stavrou (2491813), Jung-Hee Woo (2491807), David M. Neville (2491816), Geun-Bae Kim (2491804), Askale Mathias (2491801)   +6 more
core   +1 more source

Toxicity Profile of eBAT, a Bispecific Ligand-Targeted Toxin Directed to EGFR and uPAR, in Mice and a Clinical Dog Model

Toxins
EGFR-targeted therapies are efficacious, but toxicity is common and can be severe. Urokinase type plasminogen activator receptor (uPAR)-targeted drugs are only emerging, so neither their efficacy nor toxicity is fully established.
Rose H. Dicovitsky, Jill T. Schappa, Ashley J. Schulte, Haeree P. Lang, Ellen Kuerbitz, Sarah Roberts, Taylor A. DePauw, Mitzi Lewellen, Amber L. Winter, Kathy Stuebner, Michelle Buettner, Kelly Reid, Kelly Bergsrud, Sara Pracht, Andrea Chehadeh, Caitlin Feiock, M. Gerard O’Sullivan, Tim Carlson, Alexandra R. Armstrong, Danielle Meritet, Michael S. Henson, Brenda J. Weigel, Jaime F. Modiano, Antonella Borgatti, Daniel A. Vallera   +24 more
doaj   +1 more source

TAILORING IMMUNOTOXIN AS ANTICANCER DRUG

, 2012
The conventional treatments for cancer have been considered unsatisfatory, with limited efficiency in terms of discriminative cancer cell adverse reaction against the normal compartments, a number of immunological approaches had been implemented.
Huda, Nur; Research Center for Medical Science and Technology, Medical School, University of Indonesia, Asikin, Nur; Research Center for Medical Science and Technology, Medical School, University of Indonesia, Suryana, Enud J.; Research Center for Medical Science and Technology, Medical School, University of Indonesia, Baziad, Ali; Research Center for Medical Science and Technology, Medical School, University of Indonesia, Cornain, Santoso; Research Center for Medical Science and Technology, Medical School, University of Indonesia, Hambali, Hambali; Research Center for Medical Science and Technology, Medical School, University of Indonesia, Azis, Farid; Research Center for Medical Science and Technology, Medical School, University of Indonesia   +6 more
core   +1 more source

Tailoring Immunotoxin AS Anticancer Drug [PDF]

, 1989
The conventional treatments for cancer have been considered unsatisfatory, with limited efficiency in terms of discriminative cancer cell adverse reaction against the normal compartments, a number of immunological approaches had been implemented.
Asikin, N. (Nur), Cornain, S. (Santoso), Suryana, E. J. (Enud), Azis, F. (Farid), Hambali, H. (Hambali), Baziad, A. (Ali), Huda, N. (Nur)   +6 more
core